SCHEMBL193418

SCHEMBL193418

COC(=O)c1cc(N)ccc1F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.61
ABL1 P00519 1/20 0.50
ALDH1A1 P00352 7/20 0.47
KDM4E B2RXH2 5/20 0.47
HSD17B10 Q99714 4/20 0.47
MAPT P10636 3/20 0.47
HPGD P15428 3/20 0.47
GLA P06280 2/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
ATM Q13315 1/20 0.47
CFTR P13569 2/20 0.47
MAPK1 P28482 1/20 0.46
TSHR P16473 3/20 0.45
ALOX15 P16050 1/20 0.45
KMT2A Q03164 1/20 0.44
ALOX5 P09917 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.42
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31633499 1.00 GAA (0.61) GAAABL1ALDH1A1KDM4EHSD17B10
Hydrochloric Acid SCHEMBL6162273 0.98 GAA (0.59) GAAABL1ALDH1A1KDM4EHSD17B10
SCHEMBL364243 0.85 GAA (0.66) GAAABL1ALDH1A1KDM4EHSD17B10
SCHEMBL2884838 0.84 ALDH1A1 (0.47) GAAABL1ALDH1A1KDM4EHSD17B10
Hydrochloric Acid SCHEMBL3115872 0.84 GAA (0.64) GAAABL1ALDH1A1KDM4EHSD17B10
SCHEMBL1403643 0.82 GAA (0.72) GAAABL1ALDH1A1KDM4EHSD17B10
SCHEMBL112046 0.81 CES2 (0.61) ABL1ALDH1A1KDM4EHSD17B10MAPT
SCHEMBL6168887 0.81 GAA (0.66) GAAABL1ALDH1A1KDM4EHSD17B10
SCHEMBL7623605 0.81 GAA (0.70) GAAABL1ALDH1A1KDM4EHSD17B10
SCHEMBL9705197 0.81 GAA (0.65) GAAABL1ALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144743-A1 COMPOUNDS TMEM16A LIMITED (GB) 2026-05-28 US disclosed
US-20260092054-A1 FUSED RING COMPOUND AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2026-04-02 US disclosed
EP-4699655-A2 COMPOUNDS TMEM16A LIMITED (GB) 2026-02-25 EP disclosed
US-12465588-B2 Indole carboxamide derivative and pharmaceutical composition containing same KUKJE PHARMA CO., LTD. (KR) 2025-11-11 US disclosed
EP-4596539-A1 FUSED RING COMPOUND AND PHARMACEUTICAL CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2025-08-06 EP disclosed
US-12377105-B2 Compounds TMEM16A LIMITED (GB) 2025-08-05 US disclosed
CN-120192305-A Polycyclic compound containing benzene ring, pharmaceutical composition and application thereof 武汉熙瑞医药科技有限公司 2025-06-24 CN disclosed
WO-2025108234-A1 COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF 四川科伦药物研究院有限公司 2025-05-30 WO disclosed
CN-114302874-B Indole carboxamide derivatives and pharmaceutical compositions containing the same 国际药品株式会社 2025-02-25 CN disclosed
CN-119504808-A Compound, preparation method and application thereof 四川科伦药物研究院有限公司 2025-02-25 CN disclosed
CN-1325385-A Gastrin and cholecystokinin receptor ligands BLACK JAMES FOUNDATION (GB) 2001-12-05 CN disclosed
US-6239131-B1 WHICH HAVE GASTRIN AND/OR CCK-B (CHOLECYSTOKININ-B) RECEPTOR ANTAGONISM, USEFUL AS REMEDIES FOR GASTRIC ULCER AND GASTROINTESTINAL MOVEMENT DISORDER. ZERIA PHARMACEUTICAL CO., LTD. (JP) 2001-05-29 US disclosed
US-6147101-A TREATING HYPERGLYCEMIA KYORIN PHARMACEUTICAL CO., LTD. (JP) 2000-11-14 US disclosed
WO-2000027823-A1 GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS JAMES BLACK FOUNDATION LIMITED (GB) 2000-05-18 WO disclosed
US-6030990-A ANTIDIABETIC AND -LIPEMIC AGENTS; PARTICULARLY FOR NON-INSULIN DEPENDENT DIABETES MELLITUS, A BLOOD SUGAR-LOWERING DRUG THAT IMPROVES THE INSULIN RESISTANCE AND HAS HIGH SAFETY AND EFFICIENCY KYORIN PHARMACEUTICAL CO., LTD. (JP) 2000-02-29 US disclosed
US-6001862-A ADMINISTERING TO A PATIENT SUFFERING FROM NON-INSULIN DEPENDENT DIABETES MELLITUS A N-BENZYLDIOXOTHIAZOLIDYLBENZAMIDE COMPOUND KYORIN PHARAMEUTICALS CO., LTD. (JP) 1999-12-14 US disclosed
EP-0846693-A1 N-BENZYLDIOXOTHIAZOLIDYLBENZAMIDE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME KYORIN PHARMACEUTICAL CO., LTD. (JP) 1998-06-10 EP disclosed
EP-0538469-B1 SULFONANILIDE DERIVATIVE AND MEDICINE NIPPON SHINYAKU CO LTD (JP) 1995-09-27 EP disclosed
US-5360822-A FOR TREATING URINARY INCONTINENCE IN ANIMALS AND HUMANS NIPPON SHINYAKU CO. LTD. (JP) 1994-11-01 US disclosed
EP-0538469-A1 SULFONANILIDE DERIVATIVE AND MEDICINE NIPPON SHINYAKU COMPANY, LIMITED (JP) 1993-04-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260144743-A1 COMPOUNDS CACNA1E, TMEM109, CACNA1C GAA 1568/4885ABL1 3561/4885ALDH1A1 1592/4885
US-12465588-B2 Indole carboxamide derivative and pharmaceutical composition containing same PTGES, PTGES2, PTGS1 GAA 3653/4885ABL1 1412/4885ALDH1A1 331/4885
US-20260092054-A1 FUSED RING COMPOUND AND PHARMACEUTICAL CONTAINING SAME STAT6, HRH4, CCR6 GAA 2606/4885ABL1 418/4885ALDH1A1 1347/4885
US-12377105-B2 Compounds CACNA1E, TMEM109, CACNA1A GAA 1147/4885ABL1 3089/4885ALDH1A1 2218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.